I1782
イノシン一リン酸デヒドロゲナーゼ Type II ヒト
recombinant, expressed in E. coli
別名:
IMP:NADオキシドレダクターゼ, IMPDH II
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
Specific activity:
≥0.05 units/mg protein
Recombinant:
expressed in E. coli
recombinant
expressed in E. coli
form
solution
specific activity
≥0.05 units/mg protein
mol wt
~55 kDa
packaging
vial of ≥0.002 unit
UniProt accession no.
relevant disease(s)
cancer
shipped in
dry ice
storage temp.
−70°C
Quality Level
Gene Information
human ... IMPDH2(3615)
Biochem/physiol Actions
Type IIは様々ながんやリンパ球増殖に特異的に関連する、IMPDHの主要なアイソフォ-ムです。
Inosine Monophosphate Dehydrogenase Type II (IMPDH2) binds to adenosine triphosphate (ATP) and guanosine triphosphate (GTP). It catalyzes the formation of xanthosine monophosphate from inosine monophosphate in the presence of nicotinamide adenine dinucleotide (NAD). IMPDH2 elevated levels in tumors are correlated to its rate-limiting activity in guanosine monophosphate (GMP) synthesis. High levels of IMPDH2 is implicated in glioblastoma (GBM). It is regarded as a potential therapeutic target against tumors, antiviral, and immunosuppression-related pathologies.
Other Notes
1 unitは、pH 8.0、25°C、1分間で、IMPから1.0 μmolのXMPを生成し、対応するβ-NADの還元を行います。
Physical form
0.5 mMのEDTAと1 mMのDTTを含有する、pH 8.0、20 mMのトリス-HCl溶液。
Application
Inosine Monophosphate Dehydrogenase Type II human has been used to test the inhibitory effect on vacor adenine dinucleotide (VAD) on its dehydrogenase activity.
General description
Inosine Monophosphate Dehydrogenase Type II (IMPDH2) is a ubiquitously expressed dominant isoform during developmental stages. IMPDH2 gene is mapped to human chromosome 3p21.31.
保管分類
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
I1782-125UL: + I1782-BULK: + I1782-VAR: + I1782-1VL:
jan
Magdalena Makowska-Grzyska et al.
Biochemistry, 51(31), 6148-6163 (2012-07-14)
Inosine 5'-monophosphate dehydrogenase (IMPDH) catalyzes the first unique step of the GMP branch of the purine nucleotide biosynthetic pathway. This enzyme is found in organisms of all three kingdoms. IMPDH inhibitors have broad clinical applications in cancer treatment, as antiviral
Flavia Schmidt et al.
Archives of toxicology, 87(2), 361-370 (2012-08-24)
Mycophenolic acid (MPA) is an immunosuppressive agent that acts as a selective, non-reversible inhibitor of the enzyme inosine-5'-monophosphate dehydrogenase (IMPDH). Malformations have been described in children after maternal exposure to mycophenolate. However, the causal link is unclear in most cases
Veeraraghavan Usha et al.
PloS one, 7(3), e33886-e33886 (2012-04-06)
Tuberculosis (TB) remains a leading cause of mortality worldwide. With the emergence of multidrug resistant TB, extensively drug resistant TB and HIV-associated TB it is imperative that new drug targets be identified. The potential of Mycobacterium tuberculosis inosine monophosphate dehydrogenase
Magdalena Malachowska-Ugarte et al.
European journal of medicinal chemistry, 54, 197-201 (2012-05-25)
Hybrid pharmacophore anti-proliferative compounds, comprised of mycophenolic acid (MPA) and 1-nitroacridine/4-nitroacridone derivative have been synthesized and evaluated as inhibitors of five different leukemia cell lines (Jurkat, Molt-4, HL-60, CCRF-CEM, L1210) and human peripheral blood mononuclear cells from healthy donors. These
Chetan P Shah et al.
Journal of enzyme inhibition and medicinal chemistry, 33(1), 972-977 (2018-05-25)
Human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2), being an age-old target, has attracted attention recently for anticancer drug development. Mycophenolic acid (MPA), a well-known immunosuppressant drug, was used a lead structure to design and develop modestly potent and selective analogues. The
関連コンテンツ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）